1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United Kingdom >
  5. Dante Labs Acquires Cambridge Cancer Genomics

M&A Deal Summary

Dante Labs Acquires Cambridge Cancer Genomics

On June 23, 2021, Dante Labs acquired life science company Cambridge Cancer Genomics

Acquisition Highlights
  • This is Dante Labs’ 1st transaction in the Life Science sector.
  • This is Dante Labs’ 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2021-06-23
Target Cambridge Cancer Genomics
Sector Life Science
Buyer(s) Dante Labs
Deal Type Add-on Acquisition

Target

Cambridge Cancer Genomics

Cambridge, United Kingdom
Cambridge Cancer Genomics is an OncOS machine learning oncology software to create a single platform with unparalleled capabilities in genomics and oncology data analysis. Cambridge Cancer Genomics is based in Cambridge, United Kingdom.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Dante Labs

New York, New York, United States
Category Company
Founded 2016
Sector Life Science
DESCRIPTION

Dante Labs is a global genomic platform for diagnostics and pharma, built on three pillars: software, genomic database, and integration with clinical laboratories. Dante Labs is also a global provider of COVID-19 testing solutions for governments, businesses, and individuals to help people get back safely to normal life. Dante Labs was founded in 2016 and is based in New York City.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2021 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal